EGFR exon 20 mutant inhibitor, oral once-daily
Breakthrough Therapy for ex20+ NSCLC (Ph. I)
from cellular screening + SBDD
Cancer Discovery, Feb. 25, 2021
ARIAD/Takeda, Cambridge, MA
Mobocertinib (TAK-788)
4. The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon…